# Bahram Bodaghi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bahram-bodaghi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,392 |
| Field | Ocular Diseases and Behçet’s Syndrome |
| h-index | 72 |
| i10-index | 267 |
| Last Known Institution | Sorbonne Université |
| OpenAlex ID | https://openalex.org/A5086216178 |
| ORCID iD | 0000-0002-0962-5301 |
| Works | 799 |

## Researcher papers

Showing 12 of 13.

- [2018 update of the EULAR recommendations for the management of Behçet's syndrome](https://scholariq.org/papers/2018-update-of-the-eular-recommendations-for-the-management-of-behcet-s-syndrome/)
- [EULAR recommendations for the management of Behçet disease](https://scholariq.org/papers/eular-recommendations-for-the-management-of-behcet-disease/)
- [Understanding uveitis: The impact of research on visual outcomes](https://scholariq.org/papers/understanding-uveitis-the-impact-of-research-on-visual-outcomes/)
- [Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells](https://scholariq.org/papers/chemokine-sequestration-by-viral-chemoreceptors-as-a-novel-viral-escape-strategy/)
- [Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations](https://scholariq.org/papers/anti-tnf-therapy-in-the-management-of-behcet-s-disease-review-and-basis-for/)
- [Chronic Severe Uveitis](https://scholariq.org/papers/chronic-severe-uveitis/)
- [Long‐term efficacy of the interleukin‐1 receptor antagonist anakinra in ten patients with neonatal‐onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome](https://scholariq.org/papers/long-term-efficacy-of-the-interleukin-1-receptor-antagonist-anakinra-in-ten/)
- [Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease](https://scholariq.org/papers/critical-role-of-il-21-in-modulating-th17-and-regulatory-t-cells-in-behcet/)
- [Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients](https://scholariq.org/papers/efficacy-of-anti-tnf-alpha-in-severe-and-or-refractory-behcet-s-disease/)
- [IL-10 Measurement in Aqueous Humor for Screening Patients with Suspicion of Primary Intraocular Lymphoma](https://scholariq.org/papers/il-10-measurement-in-aqueous-humor-for-screening-patients-with-suspicion-of/)
- [Treatment Strategies in Primary Vitreoretinal Lymphoma](https://scholariq.org/papers/treatment-strategies-in-primary-vitreoretinal-lymphoma/)
- [New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review](https://scholariq.org/papers/new-observations-and-emerging-ideas-in-diagnosis-and-management-of-non/)

## Researcher topics

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Retinal and Optic Conditions](https://scholariq.org/topics/retinal-and-optic-conditions/)
- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Cytomegalovirus and herpesvirus research](https://scholariq.org/topics/cytomegalovirus-and-herpesvirus-research/)

## Researcher university

- [Sorbonne Université](https://scholariq.org/institutions/sorbonne-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.